I thank my colleague, Rep. Pete Olson, for sponsoring this important legislation which will be welcome news for the over 100,000,000 people afflicted with diabetes or pre-diabetes.
Joe Pitts
The Public Record
Joseph R. Pitts is a former Republican member of the U.S. House of Representatives, serving Pennsylvania's 16th congressional district from 1997 to 2017. During his tenure, Pitts was known for his focus on healthcare, energy, and family issues, often advocating for conservative policies. He played a significant role in various legislative efforts, including those related to the Affordable Care Act and energy independence. Pitts was also involved with the Pennsylvania Family Institute, reflecting his commitment to family values and social issues.
H.R. 1807, the Sickle Cell Disease Research, Surveillance, Prevention, and Treatment Act of 2015, sponsored by Rep. Danny Davis (IL) and Rep. Michael Burgess (TX) reauthorizes a sickle cell disease demonstration program.
One in five trauma deaths may be preventable or, in other words, about 30,000 people might be saved every year.
Today's hearing is an important discussion that will examine the areas where we can improve our national trauma system.
One of our main challenges in addressing emergency and trauma care is leadership.
A recent Institute of Medicine report released just last week estimates that one in five trauma deaths may be preventable.
Trauma is the number-one cause of productive life years lost, greater than cancer or heart disease.
The recent events in Orlando, Paris and San Bernardino remind us of the very real threat of mass casualty events.
We will hear from witnesses on ways to address our trauma and emergency medical systems.
I thank Mr. Murphy for his leadership and his persistence in getting this historic legislation to the floor. When a person struggles with mental illness, he or she may lose her job, her friends, even her family, which can make the mental…
So, moving forward, the committee welcomes feedback on how we can improve care for children with medical complexity without disrupting the successful approaches already in place.
I applaud the cosponsors for working through the committee to address serious stakeholder concerns by taking a new approach in the draft we are discussing today.





